Conditionally replicating adenoviruses for cancer treatment

Youssef Jounaidi, Joshua Doloff, David J. Waxman

Research output: Contribution to journalReview article

Abstract

Replication-conditional, oncolytic adenoviruses are emerging as powerful tools in the warfare on cancer. The ability to modify cell-specific infectivity or tissue-specific replication machinery, as well as the possibility of modifying viral-cellular protein interactions with cellular checkpoint regulators are emerging as new trends in the design of safer and more effective adenoviruses. The integration of oncolytic adenoviruses with mainstream cancer therapies, such as chemotherapy and radiotherapy, continues to yield significant therapeutic benefits. Adenoviruses can be armed with prodrug-activating enzymes as well as tumor suppressor genes or anti-angiogenic factors, thus providing for enhanced anti-tumor therapy and reduced host toxicity. Thus far, encouraging results have been obtained from extensive preclinical and human clinical studies. However, there is a need to improve adenoviral vectors to overcome unresolved problems facing this promising anti-cancer agent, chief among these issues is the adenovirus-triggered immune response threatening its efficacy. The continued expansion of the knowledge base of adenovirus biology will likely lead to further improvements in the design of the ideal oncolytic adenoviruses for cancer treatment.

Original languageEnglish (US)
Pages (from-to)285-301
Number of pages17
JournalCurrent Cancer Drug Targets
Volume7
Issue number3
DOIs
StatePublished - May 1 2007

Fingerprint

Adenoviridae
Neoplasms
Therapeutics
Knowledge Bases
Angiogenesis Inducing Agents
Prodrugs
Viral Proteins
Tumor Suppressor Genes
Radiotherapy
Drug Therapy
Enzymes

Keywords

  • Cancer gene therapy
  • Conditionally-replicating adenoviruses
  • Oncolytic viruses
  • Prodrug activating enzymes

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Cancer Research

Cite this

Conditionally replicating adenoviruses for cancer treatment. / Jounaidi, Youssef; Doloff, Joshua; Waxman, David J.

In: Current Cancer Drug Targets, Vol. 7, No. 3, 01.05.2007, p. 285-301.

Research output: Contribution to journalReview article

Jounaidi, Youssef ; Doloff, Joshua ; Waxman, David J. / Conditionally replicating adenoviruses for cancer treatment. In: Current Cancer Drug Targets. 2007 ; Vol. 7, No. 3. pp. 285-301.
@article{bfb3b7d0a3f44c25a27812ac0104dcc9,
title = "Conditionally replicating adenoviruses for cancer treatment",
abstract = "Replication-conditional, oncolytic adenoviruses are emerging as powerful tools in the warfare on cancer. The ability to modify cell-specific infectivity or tissue-specific replication machinery, as well as the possibility of modifying viral-cellular protein interactions with cellular checkpoint regulators are emerging as new trends in the design of safer and more effective adenoviruses. The integration of oncolytic adenoviruses with mainstream cancer therapies, such as chemotherapy and radiotherapy, continues to yield significant therapeutic benefits. Adenoviruses can be armed with prodrug-activating enzymes as well as tumor suppressor genes or anti-angiogenic factors, thus providing for enhanced anti-tumor therapy and reduced host toxicity. Thus far, encouraging results have been obtained from extensive preclinical and human clinical studies. However, there is a need to improve adenoviral vectors to overcome unresolved problems facing this promising anti-cancer agent, chief among these issues is the adenovirus-triggered immune response threatening its efficacy. The continued expansion of the knowledge base of adenovirus biology will likely lead to further improvements in the design of the ideal oncolytic adenoviruses for cancer treatment.",
keywords = "Cancer gene therapy, Conditionally-replicating adenoviruses, Oncolytic viruses, Prodrug activating enzymes",
author = "Youssef Jounaidi and Joshua Doloff and Waxman, {David J.}",
year = "2007",
month = "5",
day = "1",
doi = "10.2174/156800907780618301",
language = "English (US)",
volume = "7",
pages = "285--301",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Conditionally replicating adenoviruses for cancer treatment

AU - Jounaidi, Youssef

AU - Doloff, Joshua

AU - Waxman, David J.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Replication-conditional, oncolytic adenoviruses are emerging as powerful tools in the warfare on cancer. The ability to modify cell-specific infectivity or tissue-specific replication machinery, as well as the possibility of modifying viral-cellular protein interactions with cellular checkpoint regulators are emerging as new trends in the design of safer and more effective adenoviruses. The integration of oncolytic adenoviruses with mainstream cancer therapies, such as chemotherapy and radiotherapy, continues to yield significant therapeutic benefits. Adenoviruses can be armed with prodrug-activating enzymes as well as tumor suppressor genes or anti-angiogenic factors, thus providing for enhanced anti-tumor therapy and reduced host toxicity. Thus far, encouraging results have been obtained from extensive preclinical and human clinical studies. However, there is a need to improve adenoviral vectors to overcome unresolved problems facing this promising anti-cancer agent, chief among these issues is the adenovirus-triggered immune response threatening its efficacy. The continued expansion of the knowledge base of adenovirus biology will likely lead to further improvements in the design of the ideal oncolytic adenoviruses for cancer treatment.

AB - Replication-conditional, oncolytic adenoviruses are emerging as powerful tools in the warfare on cancer. The ability to modify cell-specific infectivity or tissue-specific replication machinery, as well as the possibility of modifying viral-cellular protein interactions with cellular checkpoint regulators are emerging as new trends in the design of safer and more effective adenoviruses. The integration of oncolytic adenoviruses with mainstream cancer therapies, such as chemotherapy and radiotherapy, continues to yield significant therapeutic benefits. Adenoviruses can be armed with prodrug-activating enzymes as well as tumor suppressor genes or anti-angiogenic factors, thus providing for enhanced anti-tumor therapy and reduced host toxicity. Thus far, encouraging results have been obtained from extensive preclinical and human clinical studies. However, there is a need to improve adenoviral vectors to overcome unresolved problems facing this promising anti-cancer agent, chief among these issues is the adenovirus-triggered immune response threatening its efficacy. The continued expansion of the knowledge base of adenovirus biology will likely lead to further improvements in the design of the ideal oncolytic adenoviruses for cancer treatment.

KW - Cancer gene therapy

KW - Conditionally-replicating adenoviruses

KW - Oncolytic viruses

KW - Prodrug activating enzymes

UR - http://www.scopus.com/inward/record.url?scp=34247887641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247887641&partnerID=8YFLogxK

U2 - 10.2174/156800907780618301

DO - 10.2174/156800907780618301

M3 - Review article

C2 - 17504125

AN - SCOPUS:34247887641

VL - 7

SP - 285

EP - 301

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 3

ER -